CJC-1295 (with DAC) Product Brief

1. Compound Overview

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone releasing hormone (GHRH).
The DAC modification significantly extends the half-life of the peptide, allowing for prolonged stimulation of growth hormone release.

CJC-1295 with DAC is commonly studied in research exploring growth hormone signaling, metabolic regulation, recovery pathways, and body composition.

2. Mechanism of Interest

CJC-1295 with DAC is studied for several biological mechanisms:

• Activation of the GHRH receptor
  • Prolonged stimulation of endogenous growth hormone release
  • Increased circulating growth hormone levels due to extended half-life
  • Potential elevation of IGF‑1 signaling pathways
  • Influence on metabolic and recovery-related pathways

3. Research Areas Being Explored

• Growth hormone regulation research
  • Body composition studies
  • Recovery and regeneration pathways
  • Metabolic signaling studies
  • Endocrine system research

4. Safety and Regulatory Notes

CJC-1295 with DAC is not approved by the FDA for medical treatment and is commonly distributed as a research compound.

This document is intended for informational and research product description purposes only.